Volanesorsen

N/A

Report date: 2022/12/05 13:53:07
NMEFirst In Class

Base Information

Drug NameVolanesorsen
Drug Alias Name伏拉索生volanesorsenumIONIS-APOCIIIIONIS-APOCIIIRxISIS-APOCIII +[9] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionApolipoprotein C-III inhibitors
TargetsApolipoprotein C-III
Therapy Area/IndicationsHypertriglyceridemiaHyperlipoproteinemiasDiabetes Mellitus, Type 2 +[7] 
Global Approved IndicationsHyperlipoproteinemia Type I
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2019/05/03
Country/TerritoryBelgiumCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAkcea Therapeutics IncIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesPtc Therapeutics IncAkcea Therapeutics Ireland Ltd
Inactive CompaniesIonis Pharmaceuticals IncAkcea Therapeutics IncNational Institute Of Diabetes And Digestive And Kidney Diseases
Active IndicationsHyperlipoproteinemia Type I
Inactive IndicationsHypertriglyceridemiaHyperlipoproteinemiasDiabetes Mellitus, Type 2 +[6] 

Other Information

ATC CodeC10AX18
Related LinksWikipediaDrugBank